The intravenous immunoglobulins market was valued at USD 17.00 billion in 2024 and is expected to grow from USD 18.40 billion in 2025 to USD 33.81 billion by 2032, reflecting a compound annual growth rate (CAGR) of 9.1% during the 2025–2032 period. North America led the market in 2024, accounting for a 57.09% share.
